Literature DB >> 31871169

Trans-endocytosis of intact IL-15Rα-IL-15 complex from presenting cells into NK cells favors signaling for proliferation.

Olga M Anton1,2, Mary E Peterson3, Michael J Hollander4, David W Dorward5, Gunjan Arora3, Javier Traba6, Sumati Rajagopalan3, Erik L Snapp7, K Christopher Garcia4, Thomas A Waldmann8, Eric O Long1.   

Abstract

Interleukin 15 (IL-15) is an essential cytokine for the survival and proliferation of natural killer (NK) cells. IL-15 activates signaling by the β and common γ (γc) chain heterodimer of the IL-2 receptor through trans-presentation by cells expressing IL-15 bound to the α chain of the IL-15 receptor (IL-15Rα). We show here that membrane-associated IL-15Rα-IL-15 complexes are transferred from presenting cells to NK cells through trans-endocytosis and contribute to the phosphorylation of ribosomal protein S6 and NK cell proliferation. NK cell interaction with soluble or surface-bound IL-15Rα-IL-15 complex resulted in Stat5 phosphorylation and NK cell survival at a concentration or density of the complex much lower than required to stimulate S6 phosphorylation. Despite this efficient response, Stat5 phosphorylation was reduced after inhibition of metalloprotease-induced IL-15Rα-IL-15 shedding from trans-presenting cells, whereas S6 phosphorylation was unaffected. Conversely, inhibition of trans-endocytosis by silencing of the small GTPase TC21 or expression of a dominant-negative TC21 reduced S6 phosphorylation but not Stat5 phosphorylation. Thus, trans-endocytosis of membrane-associated IL-15Rα-IL-15 provides a mode of regulating NK cells that is not afforded to IL-2 and is distinct from activation by soluble IL-15. These results may explain the strict IL-15 dependence of NK cells and illustrate how the cellular compartment in which receptor-ligand interaction occurs can influence functional outcome.

Entities:  

Keywords:  IL-15; cytokine; natural killer; signaling

Mesh:

Substances:

Year:  2019        PMID: 31871169      PMCID: PMC6955382          DOI: 10.1073/pnas.1911678117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

Authors:  Sigrid Dubois; Jennifer Mariner; Thomas A Waldmann; Yutaka Tagaya
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival.

Authors:  Timothy W Hand; Weiguo Cui; Yong Woo Jung; Esen Sefik; Nikhil S Joshi; Anmol Chandele; Ying Liu; Susan M Kaech
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

3.  NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha.

Authors:  Fabienne Brilot; Till Strowig; Susanne M Roberts; Frida Arrey; Christian Münz
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

Review 4.  Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis.

Authors:  Averil Ma; Rima Koka; Patrick Burkett
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

5.  Social network architecture of human immune cells unveiled by quantitative proteomics.

Authors:  Jan C Rieckmann; Roger Geiger; Daniel Hornburg; Tobias Wolf; Ksenya Kveler; David Jarrossay; Federica Sallusto; Shai S Shen-Orr; Antonio Lanzavecchia; Matthias Mann; Felix Meissner
Journal:  Nat Immunol       Date:  2017-03-06       Impact factor: 25.606

6.  Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line.

Authors:  Y Shimizu; R DeMars
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

7.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.

Authors:  J P Lodolce; D L Boone; S Chai; R E Swain; T Dassopoulos; S Trettin; A Ma
Journal:  Immunity       Date:  1998-11       Impact factor: 31.745

8.  Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain.

Authors:  J P DiSanto; W Müller; D Guy-Grand; A Fischer; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

9.  Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15.

Authors:  Aaron M Ring; Jian-Xin Lin; Dan Feng; Suman Mitra; Mathias Rickert; Gregory R Bowman; Vijay S Pande; Peng Li; Ignacio Moraga; Rosanne Spolski; Engin Ozkan; Warren J Leonard; K Christopher Garcia
Journal:  Nat Immunol       Date:  2012-10-28       Impact factor: 25.606

10.  Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice.

Authors:  Rima Koka; Patrick R Burkett; Marcia Chien; Sophia Chai; Faye Chan; James P Lodolce; David L Boone; Averil Ma
Journal:  J Exp Med       Date:  2003-04-14       Impact factor: 14.307

View more
  9 in total

1.  Cutting Edge: Inhibition of the Interaction of NK Inhibitory Receptors with MHC Class I Augments Antiviral and Antitumor Immunity.

Authors:  Abir K Panda; Arunakumar Gangaplara; Maja Buszko; Kannan Natarajan; Lisa F Boyd; Suveena Sharma; David H Margulies; Ethan M Shevach
Journal:  J Immunol       Date:  2020-06-29       Impact factor: 5.422

2.  A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities.

Authors:  Liangyin Lv; Hui Wang; Wenqiang Shi; Yang Wang; Wen Zhu; Zexin Liu; Xiaoqu Chen; Chen Zheng; Wencheng Kong; Wei Li; Jianwei Zhu; Huili Lu
Journal:  Appl Microbiol Biotechnol       Date:  2022-10-03       Impact factor: 5.560

3.  Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcεRIγ expression.

Authors:  Avishai Shemesh; Yapeng Su; Daniel R Calabrese; Daniel Chen; Janice Arakawa-Hoyt; Kole T Roybal; James R Heath; John R Greenland; Lewis L Lanier
Journal:  J Exp Med       Date:  2022-09-06       Impact factor: 17.579

4.  The RNA helicase DHX15 is a critical regulator of natural killer-cell homeostasis and functions.

Authors:  Guangchuan Wang; Xiang Xiao; Yixuan Wang; Xiufeng Chu; Yaling Dou; Laurie J Minze; Rafik M Ghobrial; Zhiqiang Zhang; Xian C Li
Journal:  Cell Mol Immunol       Date:  2022-03-23       Impact factor: 22.096

Review 5.  Transcription Factors Associated With IL-15 Cytokine Signaling During NK Cell Development.

Authors:  Xiang Wang; Xiang-Yu Zhao
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

Review 6.  Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.

Authors:  Silvia Gaggero; Kristina Witt; Mattias Carlsten; Suman Mitra
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

7.  NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.

Authors:  Takahiro Miyazaki; Mekhala Maiti; Marlene Hennessy; Thomas Chang; Peiwen Kuo; Murali Addepalli; Palakshi Obalapur; Sara Sheibani; Joanna Wilczek; Rhoneil Pena; Phi Quach; Janet Cetz; Andrew Moffett; Yinyan Tang; Peter Kirk; Jicai Huang; Dawei Sheng; Ping Zhang; Werner Rubas; Loui Madakamutil; Saul Kivimäe; Jonathan Zalevsky
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 12.469

8.  When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer.

Authors:  Mohamed S Hasim; Marie Marotel; Jonathan J Hodgins; Elisabetta Vulpis; Olivia J Makinson; Sara Asif; Han-Yun Shih; Amit K Scheer; Olivia MacMillan; Felipe G Alonso; Kelly P Burke; David P Cook; Rui Li; Maria Teresa Petrucci; Angela Santoni; Padraic G Fallon; Arlene H Sharpe; Giuseppe Sciumè; André Veillette; Alessandra Zingoni; Douglas A Gray; Arleigh McCurdy; Michele Ardolino
Journal:  Sci Adv       Date:  2022-04-13       Impact factor: 14.957

Review 9.  Natural killer cells in antitumour adoptive cell immunotherapy.

Authors:  Tamara J Laskowski; Alexander Biederstädt; Katayoun Rezvani
Journal:  Nat Rev Cancer       Date:  2022-07-25       Impact factor: 69.800

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.